Affimed

Affimed N.V.
Stock Exchange NASDAQ Stock Market
EPS
$0.18
Market Cap
$181.67 M
Shares Outstanding
62.43 M
Public Float
47.61 M

Profile

Address
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.affimed.com
Updated 07/08/2019
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Financials

View All

Mathieu Simon
Member-Supervisory Board
Ulrich M. Grau
Member-Supervisory Board